INDV

It has been about a month since the last earnings report for Indivior Pharmaceuticals Inc. (INDV). Shares have lost about 5.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Indivior Pharmaceuticals Inc. due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Indivior Beats Q2 Earnings Estimates, 2026 Outlook Raised Indivior delivered adjusted earnings of $1.15 per share in the second quarter of 2026, up 125.5% year over year and beating the Zacks Consensus Estimate of 97 cents.Total revenues rose 13.6% year over year to $343 million, primarily due to strong U.S. Sublocade performance. The metric beat the Zacks Consensus Estimate of $308 million.Total Sublocade net revenues increased 21% year over year to a quarterly record of $253 million.U.S. Sublocade revenues increased 22% to $238 million, driven by strong dispense unit volume growth, favorable price/mix and gross-to-net adjustments.Dispense unit volume increased 18% year over year, supported by strong market demand and commercial execution.The quarter saw record new patient starts for the company, with roughly 32,816 patients beginning Sublocade treatment. As of June 30, 2026, more than 545,000 U.S. patients had been prescribed Sublocade since launch.U.S. sublingual and other product revenues increased to $57 million compared with $52 million in the prior-year quarter. Rest of World revenues declined 6.5% year over year to $43 million.In the second quarter of 2026, overall U.S. revenues rose to $300 million, up from $256 million a year ago. Indivior's Cost Base Lifts Profitability Indivior continued to improve profitability through disciplined cost management. Adjusted operating expenses declined 33% year over year to $112 million.Adjusted EBITDA surged 111% year over year to $186 million. Balance Sheet & Share Repurchases The company ended the quarter with $249 million in cash and investments, up from $201 million as of March 31, 2026. During the quarter, the company repurchased about 4.7 million shares for $175 million at an average price of $37.52. Indivior Raises 2026 Outlook Reflecting stronger-than-expected commercial performance, Indivior increased its full-year 2026 financial guidance.The company expects net revenues to be in the range of $1.295-$1.365 billion, up from its previous guidance of $1.215-$1.285 billion.Indivior also lifted its total Sublocade net revenues forecast to $1.01-$1.05 billion from $950-$990 million, implying approximately 20% year-over-year growth at the midpoint.The increase in guidance reflects stronger-than-expected dispense-unit growth and improved commercial dispense yields, supported by favorable product mix trends.Adjusted EBITDA is projected at $700-$740 million, up from the prior range of $620-$660 million. The adjusted operating expense outlook was maintained at $430-$450 million. In the past month, investors have witnessed a upward trend in estimates review. Currently, Indivior Pharmaceuticals Inc. has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a score of B on the value side, putting it in the second quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise Indivior Pharmaceuticals Inc. has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Indivior Pharmaceuticals Inc. is part of the Zacks Medical - Drugs industry. Over the past month, Ionis Pharmaceuticals (IONS), a stock from the same industry, has gained 8.7%. The company reported its results for the quarter ended June 2026 more than a month ago. Ionis Pharmaceuticals reported revenues of $268 million in the last reported quarter, representing a year-over-year change of -40.7%. EPS of -$0.43 for the same period compares with $0.86 a year ago. For the current quarter, Ionis Pharmaceuticals is expected to post a loss of $0.89 per share, indicating a change of -45.9% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.1% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Ionis Pharmaceuticals. Also, the stock has a VGM Score of F. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Indivior Pharmaceuticals INDV has announced a definitive agreement to merge with Supernus Pharmaceuticals SUPN in a tax-free, all-stock merger of equals. The transaction will create a leading central nervous system (CNS)-focused biopharmaceutical company with a diversified portfolio of 11 marketed medicines spanning psychiatry, neurology and addiction. Under the agreement, Indivior shareholders will own approximately 56.5% of the combined company, while Supernus shareholders will hold the remaining 43.5%. The transaction is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals and customary closing conditions. Following completion, the combined company will be headquartered at Supernus' existing headquarters and will continue trading on Nasdaq under the ticker SUPN. On a pro forma basis, the merged entity is expected to generate approximately $2.2 billion in annual revenues, $888 million in adjusted EBITDA and achieve $125 million in annual cost synergies. The proposed merger with Supernus is expected to strengthen the combined company's research and development capabilities by integrating Indivior's leadership in addiction medicine with Supernus' broader CNS expertise. The merged organization also plans to advance Supernus' innovative pipeline programs while pursuing additional business development opportunities to further expand its CNS portfolio. Indivior also announced its second-quarter 2026 results. Adjusted earnings were $1.15 per share, up 125.5% year over year, and beating the Zacks Consensus Estimate of 97 cents. Total revenues rose 13.6% year over year to $343 million, primarily driven by strong U.S. Sublocade performance. The metric beat the Zacks Consensus Estimate of $308 million. Despite the better-than-expected quarterly performance, INDV shares declined by 6.6%, likely as investors reacted negatively to the merger announcement. Year to date, shares of Indivior have risen 4.1% against the industry’s 4.4% decline. Image Source: Zacks Investment Research Total Sublocade net revenues increased 21% year over year to a quarterly record of $253 million. U.S. Sublocade revenues increased 22% to $238 million, driven by strong dispense unit volume growth, favorable price/mix and gross-to-net adjustments. Dispense unit volume increased 18% year over year, supported by strong market demand and commercial execution. The quarter saw record new patient starts for the company, with roughly 32,816 patients beginning Sublocade treatment. As of June 30, 2026, more than 545,000 U.S. patients had been prescribed Sublocade since launch. U.S. sublingual and other product revenues increased to $57 million compared with $52 million in the prior-year quarter. Perseris revenues declined to $5 million from $8 million, while Rest of World revenues declined 6.5% year over year to $43 million. In the second quarter of 2026, overall U.S. revenues rose to $300 million, up from $256 million a year ago. Indivior continued to improve profitability through disciplined cost management. Adjusted operating expenses declined 33% year over year to $112 million. Adjusted EBITDA surged 111% to $186 million. Indivior ended the quarter with $249 million in cash and investments, up from $201 million as of March 31, 2026. During the quarter, the company repurchased about 4.7 million shares for $175 million at an average price of $37.52. Reflecting stronger-than-expected commercial performance, Indivior increased its full-year 2026 financial guidance. The company expects net revenues of $1.295-$1.365 billion, up from its previous guidance of $1.215-$1.285 billion. Indivior also lifted its total Sublocade net revenue forecast to $1.01-$1.05 billion from $950-$990 million, implying approximately 20% year-over-year growth at the midpoint. The increase in guidance reflects stronger-than-expected dispense-unit growth and improved commercial dispense yields, supported by favorable product mix trends. Adjusted EBITDA is projected at $700-$740 million, up from the prior range of $620-$660 million. The adjusted operating expense outlook was maintained at $430-$450 million. Indivior Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Indivior Pharmaceuticals Inc. Quote Indivior currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 90 days, earnings per share estimates for Harmony Biosciences have decreased from $3.34 to $3.30 for 2026. Over the same period, estimates for earnings per share increased from $3.79 to $3.87 for 2027. HRMY shares have lost 4.9% year to date. Harmony Biosciences missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 25.16%. Over the past 90 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $5.31 from $2.91. LQDA shares have gained 143.1% year to date. Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report Supernus Pharmaceuticals, Inc. (SUPN) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Indivior PLC? Here are five stocks we like better. Indivior and Supernus plan an all-stock merger of equals expected to close in Q4 2026, subject to approvals. The combined company will retain the Supernus name, be headquartered in Maryland and be led by Supernus CEO Jack Khattar. The merged business would generate approximately $2.2 billion in pro forma annual revenue, led by Indivior’s SUBLOCADE, which is expected to contribute about 44% of revenue. Key products will span addiction, ADHD, depression and Parkinson’s disease. Management expects $125 million in annual cost synergies within the first year after closing, with pro forma adjusted EBITDA of about $888 million and net leverage near one times. Indivior will also declare a $1 billion aggregate dividend to its pre-closing shareholders. Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The transaction is expected to close in the fourth quarter of 2026, subject to shareholder approvals, regulatory clearances and customary closing conditions. Until then, the companies will continue operating independently. → Lost in Space: Why Aerospace Valuations Are Plummeting Right Now Under the agreement, Supernus shareholders will receive 1.5401 shares of Indivior common stock for each Supernus share held. Indivior also plans to declare a $1 billion aggregate dividend to its pre-closing shareholders before the deal is completed. At closing, Indivior shareholders are expected to own about 56.5% of the combined company on a fully diluted basis, while Supernus shareholders would own approximately 43.5%. The combined company will retain the Supernus name and be headquartered in Rockville, Maryland. Supernus President and Chief Executive Officer Jack Khattar will lead the company after closing, while Indivior director Tony Kingsley will serve as non-executive chairman. The board is expected to include four directors from each company, including Khattar and Kingsley. → MarketBeat Week in Review – 07/27- 07/31 Khattar said the combination would bring together 11 commercial medicines across four primary therapeutic areas: addiction, attention-deficit/hyperactivity disorder, depression and Parkinson’s disease. “This transaction creates a CNS leader through the combination of two highly complementary businesses,” Khattar said. He added that the companies expect their key growth products to continue growing into the 2030s. → GE HealthCare Stock Climbs on Vital Diagnostics Demand Indivior CEO Joe Ciaffoni said the deal follows the company’s efforts under its Indivior Action Agenda, which focused on expanding sales of opioid use disorder treatment SUBLOCADE, simplifying the organization and strengthening its financial position. He said the merger gives Indivior shareholders an opportunity to participate in the upside of the combined company. As of June 30, the combined business had approximately $2.2 billion in pro forma net revenue over the preceding 12 months. SUBLOCADE, Indivior’s extended-release buprenorphine injection for opioid use disorder, is expected to account for about 44% of that revenue, making it the combined company’s largest individual product contributor. The portfolio also includes Indivior’s SUBOXONE sublingual film for opioid use disorder and Supernus growth products including Qelbree for ADHD, ZURZUVAE for postpartum depression and Onapgo for Parkinson’s disease. Khattar also identified Gocovri among the products the combined company expects to support. Ciaffoni said SUBLOCADE remains the leading prescribed long-acting injectable treatment in its market and reported that the product had record new patient starts in the latest quarter. He said market share was stable at 76% for roughly six or seven quarters. While declining to provide peak-sales guidance, Ciaffoni said Indivior sees a durable growth runway for SUBLOCADE. He cited a large untreated patient population and low long-acting injectable penetration, which he said stands at about 10%. According to Ciaffoni, an estimated eight million to nine million people in the U.S. misuse opioids, four million to five million are diagnosed with opioid use disorder, and about two million receive buprenorphine treatment. He said Indivior’s consumer education and awareness efforts are intended to encourage more patients to seek treatment. The company said prompted awareness of SUBLOCADE among current or recent buprenorphine users rose to 50% in its most recent research from 15% before it began its consumer-focused investment. Ciaffoni also said SUBLOCADE has more than 85% access across commercial and Medicaid coverage. The companies expect to achieve $125 million in annual cost synergies within the first 12 months after the merger closes. Khattar said the savings are expected to come primarily from general and administrative redundancies and operational efficiencies. Management did not provide detailed estimates for potential additional savings, but Khattar said the combined company would continue reviewing operations for further efficiency opportunities after closing. Supernus CFO Tim Dec said the company’s past acquisition and integration experience supports its confidence in delivering the stated synergy target. For the 12 months ended June 30, Supernus reported $830 million in net revenue and $150 million in adjusted EBITDA, representing an approximately 18% adjusted EBITDA margin. Indivior reported $1.3 billion in net revenue and $613 million in adjusted EBITDA, or a 46% margin. On a pro forma basis, including anticipated synergies, the combined company would have generated approximately $888 million in adjusted EBITDA, representing a margin of roughly 41%. Pro forma net debt was cited at $878 million, equal to about one times net leverage. Dec said the combined company would have approximately 215 million shares outstanding based on the exchange ratio. Khattar said the larger company intends to remain disciplined in business development, with CNS as its primary strategic focus. He said Supernus would also continue to consider women’s health opportunities and could pursue products spanning psychiatry, neurology and certain rare diseases. The company expects to prioritize commercial-stage and mid- to late-stage assets, while continuing to invest in its existing development pipeline and discovery programs. Khattar said the greater scale and financial resources of the combined business could support opportunities neither company could pursue independently. Management does not expect meaningful sales-force consolidation between Supernus’ existing areas and Indivior’s opioid use disorder business. Khattar said the company anticipates maintaining four distinct sales forces focused on ADHD, Parkinson’s disease, obstetrics and gynecology, and SUBLOCADE. Regarding SUBLOCADE’s durability, Ciaffoni said the product is a complex sterile long-acting injectable made through an aseptic manufacturing process. He said the company has 12 Orange Book-listed patents extending from 2031 through 2038 and is pursuing additional patents related to a 2025 label update that, if granted, could extend intellectual property protection to 2042 through 2044. Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management. Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Indivior Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +18.56%. A quarter ago, it was expected that this company would post earnings of $0.64 per share when it actually produced earnings of $0.96, delivering a surprise of +50%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Indivior Pharmaceuticals Inc., which belongs to the Zacks Medical - Drugs industry, posted revenues of $343 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 11.36%. This compares to year-ago revenues of $302 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Indivior Pharmaceuticals Inc. shares have added about 11.5% since the beginning of the year versus the S&P 500's gain of 9.4%. While Indivior Pharmaceuticals Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Indivior Pharmaceuticals Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.03 on $313.35 million in revenues for the coming quarter and $4.05 on $1.26 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Ardelyx (ARDX), is yet to report results for the quarter ended June 2026. The results are expected to be released on August 6. This biotechnology company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of +37.5%. The consensus EPS estimate for the quarter has been revised 14.3% lower over the last 30 days to the current level. Ardelyx's revenues are expected to be $123.69 million, up 26.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report Ardelyx, Inc. (ARDX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

•   Q2’26 Total Net Revenue of $343 Million, Up 14% YoY •   Record Quarterly Total SUBLOCADE® Net Revenue of $253 Million in Q2'26, Up 21% YoY •   Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net Income of $142 Million in Q2'26 •   Record Quarterly Adjusted EBITDA of $186 Million in Q2'26, Up 111% YoY •   Repurchased Approximately 4.7 Million Shares in Q2'26 for $175 Million RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) --  Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the second quarter ended June 30, 2026, and raised its full-year 2026 financial guidance. “Exceptional operational execution in Phase II – Accelerate – of the Indivior Action Agenda fueled strong SUBLOCADE performance in the quarter and is the primary driver of our raised 2026 guidance,” said Joe Ciaffoni, Chief Executive Officer. "We remain focused on Phase II – Accelerate – for the remainder of 2026 and look forward to closing our proposed merger with Supernus, which is expected in the fourth quarter. Upon the close of our proposed merger, all three Phases of the Indivior Action Agenda will have been successfully completed.” “We delivered record SUBLOCADE net revenue and adjusted EBITDA in the quarter leading us to raise our 2026 guidance,” said Ryan Preblick, Chief Financial Officer. "We now expect 2026 total SUBLOCADE net revenue growth of 20% year-over-year and adjusted EBITDA growth of 68% year-over-year at the midpoint of our guidance ranges. We returned capital to our shareholders through the repurchase of $175 million in shares during the quarter. We are committed to creating long-term shareholder value.” Q2 2026 Business Highlights: As of June 30, 2026, over 545,000 patients in the U.S. have been prescribed SUBLOCADE since launch. Grew total SUBLOCADE net revenue 21% year-over-year to $253 million. U.S. SUBLOCADE net revenue increased 22% year-over-year to $238 million versus the prior year, driven by 18% dispense unit volume growth. New patient starts of 32,816 were a record. Net revenue also benefited from more favorable price/mix and gross-to-net adjustments. In the second quarter, Indivior repurchased 4,664,540 shares at an average price of $37.52 for a total of $175 million. Year-to-date, the Company has repurchased 8,638,693 shares at an average price of $34.73 for a total of $300 million. Announced findings from two new real-world evidence studies showing that adherence to SUBLOCADE is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD). Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. today announced a definitive agreement to combine in an all-stock merger of equals transaction to create a leading, diversified, scaled, CNS-focused biopharmaceutical company. For additional information on the transaction, please reference the announcement press release at Indivior.com. Raising Full-Year 2026 Financial Guidance: Full-year financial guidance assumes no material change in exchange rates for key currencies compared with 2025 average rates, notably USD/GBP and USD/EUR. *We have not provided the forward-looking U.S. GAAP equivalents for certain forward-looking non-U.S. GAAP metrics as a result of the uncertainty and potential variability of reconciling items. Accordingly, the Company has relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K to exclude such reconciliations, as the reconciliations of these non-U.S. GAAP guidance metrics to their corresponding U.S. GAAP equivalents are not available without unreasonable effort. Financial Results for Quarter Ended June 30, 2026: Total net revenue was $343 million for the quarter ended June 30, 2026 (the 2026 quarter), compared to $302 million for the quarter ended June 30, 2025 (the 2025 quarter), representing a 14% increase year-over-year. Total SUBLOCADE net revenue was $253 million for the 2026 quarter, compared to $209 million for the 2025 quarter, representing a 21% increase year-over-year. GAAP operating expenses were $134 million for the 2026 quarter, compared to $179 million for the 2025 quarter, representing a 25% decrease year-over-year. Non-GAAP operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were $112 million for the 2026 quarter, compared to $167 million for the 2025 quarter, representing a 33% decrease year-over-year. GAAP net income for the 2026 quarter was $122 million ($0.98 diluted earnings per share), compared to GAAP net income for the 2025 quarter of $18 million ($0.14 diluted earnings per share). Non-GAAP net income for the 2026 quarter was $142 million ($1.15 diluted earnings per share), compared to non-GAAP net income for the 2025 quarter of $64 million ($0.51 diluted earnings per share). Adjusted EBITDA for the 2026 quarter was $186 million, compared to $88 million for the 2025 quarter, representing a 111% increase year-over-year. The Company ended the 2026 quarter with cash and investments of $249 million. Financial Results for Six Months Ended June 30, 2026: Total net revenue was $660 million for the six months ended June 30, 2026 (the 2026 period), compared to $568 million for the six months ended June 30, 2025 (the 2025 period), representing a 16% increase year-over-year. Total SUBLOCADE net revenue was $486 million for the 2026 period, compared to $385 million for the 2025 period, representing a 26% increase year-over-year. GAAP operating expenses were $273 million for the 2026 period, compared to $334 million for the 2025 period, representing an 18% decrease year-over-year. Non-GAAP operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were $229 million for the 2026 period, compared to $313 million for the 2025 period, representing a 27% decrease year-over-year. GAAP net income for the 2026 period was $211 million ($1.67 diluted earnings per share), compared to GAAP net income for the 2025 period of $65 million ($0.52 diluted earnings per share). Non-GAAP net income for the 2026 period was $266 million ($2.10 diluted earnings per share), compared to non-GAAP net income for the 2025 period of $121 million ($0.96 diluted earnings per share). Adjusted EBITDA for the 2026 period was $350 million, compared to $165 million for the 2025 period, representing a 112% increase year-over-year. Conference Call and Webcast Details:As a result of the transaction announcement today, Indivior will host a joint transaction conference call with Supernus in lieu of its previously scheduled second quarter 2026 earnings conference call. A live webcast will be available here or from the Investor Relations section of both companies’ website at Supernus Events & Presentations and www.indivior.com. Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time. A replay of the webcast will be available following the event. An investor presentation, which will be referenced during the webcast, is also available from the Investor Relations section of both companies' websites. About Indivior As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior. Columns and rows within financial tables may not foot due to rounding. Percentages and per share data in the financial tables have been calculated using actual, non-rounded figures. Non-GAAP Financial Measures: Non-GAAP financial measures adjust for non-recurring items and other items representing expenses or income that we believe do not reflect the Company’s ongoing operations or the adjustment of which may help with the comparison to prior periods. The Company believes its non-GAAP financial measures may be useful to investors to understand the Company’s performance. In addition, the Company uses “Adjusted EBITDA” in its annual incentive plan in which all executive officers participate. Important Cautionary Note Regarding Forward-Looking Statements: This announcement contains certain statements that are forward-looking statements. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements include, among other things, express and implied statements regarding: our 2026 financial guidance including with respect to net revenue, total SUBLOCADE net revenue, non-GAAP operating expenses, and adjusted EBITDA; potential business development opportunities to acquire the next commercial stage growth drivers; potential expense reductions; expected acceleration in SUBLOCADE net revenue and dispense unit growth; expected growth in adjusted EBITDA, cash flow, and our bottom line, and expected acceleration of such growth; potential future share repurchases; expected creation of shareholder value; anticipated benefits of the proposed merger with Supernus, the expected timing of completion of the proposed merger, estimated costs associated with the proposed merger, and other statements containing the words "believe," "anticipate," "plan," "expect," "intend," "estimate," "forecast," “strategy,” “target,” “guidance,” “outlook,” “potential,” "project," "priority," "may," "will," "should," "would," "could," "can," the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and only express management’s beliefs regarding future results or events which, by their nature, are inherently uncertain and outside of management’s control or ability to predict. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including but not limited to: lower than expected future sales of our products; greater than expected impacts from competition; and unanticipated costs including the effects of potential tariffs and potential retaliatory tariffs; market conditions; the decisions of third parties outside of our control with respect to potential business development opportunities; the risk that the proposed merger with Supernus may not be completed on the anticipated timeline or at all; the failure to obtain required stockholder or regulatory approvals for the merger, or the imposition of conditions in connection with such approvals; the risk that the anticipated benefits, synergies, growth, profitability, cash flow generation and earnings accretion of the merger are not realized or are realized more slowly than expected; and risks relating to the integration of the two businesses. For additional information about some of the risks and important factors that could affect our future results and financial condition, see “Important Cautionary Note Regarding Forward-looking Statements” and "Risk Factors" in Indivior's Annual Report on Form 10-K filed February 26, 2026, and our other filings with the U.S. Securities and Exchange Commission. We have based the forward-looking statements in this report on our current expectations and beliefs concerning future events. Forward-looking statements contained in this report speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether due to new information, or to reflect events or developments that occur after the date the statement was made. Important Additional Information and Where to Find It In connection with the proposed transaction, Indivior intends to file with the SEC a registration statement on Form S-4, which will include a document that serves as a prospectus of Indivior and a joint proxy statement of Indivior and Supernus (the “joint proxy statement/prospectus”). Each party also plans to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. A definitive joint proxy statement/prospectus will be sent to Indivior’s stockholders and Supernus’ stockholders. Investors and securityholders may obtain a free copy of the joint proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by Indivior and Supernus with the SEC at the SEC’s website at www.sec.gov. Copies of the documents filed by Indivior with the SEC will be available free of charge on Indivior’s website at www.indivior.com or by contacting Indivior’s Investor Relations at [email protected]. Copies of the documents filed by Supernus with the SEC will be available free of charge on Supernus’ website at www.supernus.com. No Offer or Solicitation This communication and the information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Participants in the Solicitation Indivior and Supernus and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about directors and executive officers of Indivior is available in the Indivior proxy statement for its 2026 Annual Meeting, which was filed with the SEC on March 27, 2026. Information about directors and executive officers of Supernus is available in the Supernus proxy statement for its 2026 Annual Meeting, which was filed with the SEC on April 30, 2026. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC regarding the proposed transaction when they become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. Investors may obtain free copies of these documents from Indivior and Supernus as indicated above. For Further Information 1Marketing and promotion activities for PERSERIS were discontinued in 2024. Reconciliation of GAAP to non-GAAP financial information 1Includes severance, consulting, impairment, and costs related to planned facility closures. Non-GAAP diluted earnings per shareManagement believes that non-GAAP diluted earnings per share, which excludes the impact of certain non-recurring items and other adjustments, net of applicable tax effects, may provide useful information to shareholders regarding underlying trends in earnings per share. A reconciliation of GAAP net income to non-GAAP net income, as well as the weighted average shares used in computing non-GAAP diluted earnings per share, is included in the table below. 1Includes manufacturing transition and other costs Adjusted EBITDAAdjusted EBITDA is a non-GAAP financial measure that represents GAAP net income adjusted to exclude interest expense, interest income, income tax expense or benefit, depreciation and amortization, stock-based compensation, and other adjustments reflecting changes in our business that do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

Sanofi SNY announced that it is discontinuing the phase III MOBILIZE study, which is evaluating its investigational drug, riliprubart, in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care (SoC) treatment. This decision comes after an independent committee conducted an interim analysis of the data from the MOBILIZE study and concluded that riliprubart was “unlikely to provide sufficient efficacy” in this difficult-to-treat patient population. The analysis did not identify any new safety concerns associated with the drug. With this setback, Sanofi stated that it will assess the future of other ongoing riliprubart studies, including the phase III VITALIZE study in CIDP patients receiving maintenance intravenous immunoglobulin (IVIg) therapy. CIDP is a rare disorder affecting the peripheral nervous system, marked by progressive muscle weakness and sensory loss. Following this announcement, Sanofi's shares were trading lower in pre-market trading today. While the company assured investors that the MOBILIZE study termination does not affect its financial outlook for 2026, the setback raises concerns about the future of riliprubart, which was previously viewed as one of its promising pipeline candidates. Sanofi had previously outlined plans for a regulatory filing in 2027 based on data from the MOBILIZE and VITALIZE studies. The drug has also secured orphan drug designation in both the United States and Europe for CIDP. Although VITALIZE remains ongoing, the loss of one pivotal study raises uncertainty about riliprubart's regulatory and commercial prospects. Year to date, the stock has lost nearly 8% against the industry’s 4% growth. Image Source: Zacks Investment Research An investigational IgG4 humanized monoclonal antibody, riliprubart, is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system. Apart from CIDP, Sanofi is assessing riliprubart in a phase II study for antibody-mediated rejection (AMR) in kidney transplant recipients. The study is evaluating the drug in patients at risk of developing AMR as well as those with active AMR, reflecting the company's efforts to explore the therapy's potential across multiple immune-mediated diseases. Sanofi currently carries a Zacks Rank #3 (Hold). Sanofi price | Sanofi Quote Some better-ranked stocks from the sector are Immunocore IMCR and Indivior Pharmaceuticals INDV, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost 18% year to date. Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%. Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.66 to $4.27. INDV’s shares are up nearly 7% year to date. Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Shares of BioMarin Pharmaceutical BMRN were down 4% on Monday after it reported results from the phase III ENERGY 3 study, which evaluated BMN 401, an investigational enzyme replacement therapy (ERT), for a rare genetic disorder called ENPP1 deficiency in children aged 1 to 12. The study did not meet one of its two main goals. The mixed results were a setback for BioMarin, which added BMN 401 through its $270 million acquisition of Inozyme Pharma last year. This ERT was the lead asset in Inozyme’s pipeline, and the ENERGY 3 study was already underway at the time of the acquisition. Year to date, the stock has lost 16% compared with the industry’s 3% fall. Image Source: Zacks Investment Research The study assessed two primary endpoints — changes in plasma inorganic pyrophosphate (PPi) and Radiographic Global Impression of Change (RGI-C) scores after 52 weeks of treatment. While treatment with BMN 401 after 52 weeks resulted in statistically significant increases in plasma PPi, there was no corresponding improvement in RGI-C scores. An increase in plasma PPi is considered an important biomarker response because ENPP1 deficiency leads to low PPi levels, which can result in progressive damage to blood vessels, soft tissues and bones. However, BMN 401 failed to demonstrate improvement in RGI-C scores, a key measure used to assess treatment impact in children with rickets. The lack of radiographic improvement suggests that the biomarker gains did not translate into measurable skeletal benefits during the study period. The therapy also did not show positive trends across secondary endpoints, including Rickets Severity Score (RSS), a measure of rickets severity, and growth Z-scores evaluating height/body length and weight. BioMarin stated that it will continue analyzing the complete ENERGY 3 dataset and engage with global regulatory authorities to determine the next steps for BMN 401’s development program. The company also plans to present detailed findings from the study at a future medical meeting. The stock currently carries a Zacks Rank #3 (Hold). BioMarin Pharmaceutical Inc. price | BioMarin Pharmaceutical Inc. Quote Some better-ranked stocks from the sector are Immunocore IMCR and Indivior Pharmaceuticals INDV, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 30 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. Over the same period, estimates for 2027 have improved from a loss of 39 cents to earnings of 11 cents. IMCR shares have lost 18% year to date. Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%. Over the past 30 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.10 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.47. INDV shares have risen 2% year to date. Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

CorMedix Therapeutics CRMD delivered first-quarter 2026 diluted earnings of 43 cents per share, up 43.3% year over year, beating the Zacks Consensus Estimate of 35 cents. Net revenue was $127.4 million, up significantly from the year-ago sales of $39.08 billion. The reported figure beat the Zacks Consensus Estimate of $110 million. Results reflected stronger DefenCath execution and underlying demand trends, with DefenCath net revenues of $97.5 million in the quarter. Management also lifted its full-year outlook following the better-than-expected start to 2026. The stock gained 5.7% on Thursday following the earnings release. DefenCath remained the key operating lever in the period, supported by higher utilization among outpatient dialysis customers. Its sales increased, primarily boosted by the onboarding of a large dialysis organization in mid-2025, along with strong positive demand trends. Quarterly DefenCath performance also benefited from a favorable change in estimate tied to certain sales allowances, including items such as Medicaid rebates and product returns. While that impact provided a lift, management pointed to underlying utilization momentum as the more important signal on demand durability. The Melinta portfolio contributed $29.9 million in the first quarter. Its acquisition in the last year added a meaningful second revenue stream and broadened CorMedix’s commercial footprint. The Melinta contribution also changed the year-over-year comparison framework for CorMedix, given that the acquisition occurred in August 2025. As a result, the year-ago period reflected revenue from only DefenCath, making the current quarter’s mix and scale structurally different. Shares of CorMedix have plunged 31.9% so far this year against the industry’s 1.1% growth. Image Source: Zacks Investment Research Operating expenses increased sharply year over year as the company absorbed a larger cost base following the Melinta acquisition. Total operating expenses were $41.5 million, up 138.5% from the prior-year quarter, which management attributed primarily to expenses related to the acquired portfolio and the broader combined-company footprint. R&D expenses climbed to $7.2 million, up 125% year over year, due to higher personnel spending and clinical trial services tied to ongoing programs, including pediatric studies for certain brands and continued DefenCath development work. Commercial and corporate costs also rose with scale, as selling and marketing expenses increased significantly to $12.5 million and general and administrative expenses rose abruptly to $21.7 million, reflecting the expanded portfolio and related operating requirements. Management raised its full-year 2026 net revenue outlook to the range of $325-$345 million from $300-$320 million, citing strong first-quarter execution and continued confidence in underlying demand. The revised range represents an increase from CRMD’s previously established revenue expectations. CorMedix also increased full-year adjusted EBITDA guidance to a range of $115-$135 million from $100-$125 million. The updated profitability view suggests management expects operating leverage to continue as the company integrates the broader product set and sustains DefenCath utilization growth. CorMedix highlighted progress across its late-stage pipeline in the first-quarter earnings release. Last month, the company announced positive phase III top-line results from the global ReSPECT clinical study evaluating Rezzayo (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation. CorMedix said it is working with its global partner to prepare a supplemental new drug application expected to be submitted in the second half of this year, with a potential commercial launch for the expanded indication in 2027. CorMedix also provided an update on its ongoing phase III study of taurolidine/heparin catheter lock solution in total parenteral nutritionpatients, which continues to enroll and is currently trending to completion in 2028. Management noted it is taking steps to accelerate enrollment, including opening new study sites and submitting a protocol amendment to the FDA that, if approved, would remove certain exclusion criteria and broaden patient enrollment. CorMedix Inc price-consensus-eps-surprise-chart | CorMedix Inc Quote CorMedix currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the biotech sector are Amarin Corporation AMRN, Indivior Pharmaceuticals INDV and Immunocore IMCR, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have also narrowed from $5.50 to $4.64. AMRN shares have risen 5.9% year to date. Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 50.02%. Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV shares have risen 5.4% year to date. Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%. Over the past 60 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. On the other hand, its 2026 EPS is currently pegged at 11 cents. IMCR shares have lost 17.2% year to date. Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report CorMedix Inc (CRMD) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Catalyst Pharmaceuticals CPRX reported adjusted earnings of 79 cents per share for the first quarter of 2026, beating the Zacks Consensus Estimate of 64 cents. The company had recorded adjusted earnings of 68 cents in the year-ago quarter. Total revenues, the majority of which comprised product revenues, amounted to $149.4 million in the reported quarter, representing growth of 6% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $147 million. Catalyst Pharmaceuticals’ top line primarily comprised revenues from the sale of Firdapse, the first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and the newer muscle disease drug, Agamree (vamorolone). Revenues generated from the sale of CPRX’s epilepsy drug Fycompa (perampanel) CIII also contributed to the top line. Firdapse generated sales worth $98.86 million in the reported quarter, up 18% year over year, driven by organic sales growth. The reported figure marginally missed the Zacks Consensus Estimate of $98.9 million. The drug has been witnessing strong demand, increasing prescription rates from LEMS patients and continued diagnosis of new LEMS patients. In 2023, Catalyst Pharmaceuticals acquired exclusive rights to manufacture and supply Agamree from Santhera Pharmaceuticals through a licensing agreement. In late 2023, the FDA approved Agamree for treating Duchenne Muscular Dystrophy in patients aged two years and older, which gave the company a third approved product. The drug was commercially launched in the United States in the middle of March 2024. In the reported quarter, Agamree generated revenues worth $36.7 million, up 67% year over year. The reported figure beat the Zacks Consensus Estimate of $35 million. Year to date, Catalyst Pharmaceuticals shares have gained 33.5% against the industry’s 4.7% decline. Image Source: Zacks Investment Research In 2023, Catalyst Pharmaceuticals acquired the U.S. rights for Fycompa (perampanel) CIII from Eisai Co., Ltd. This acquisition diversified the company’s portfolio by adding a commercial-stage epilepsy asset. Catalyst Pharmaceuticals started recording sales of Fycompa in 2023. Fycompa generated net product revenues of $13.8 million, down 61% year over year, as tablet generics began hitting the market in May 2025 following the expiration of its first U.S. patent, with another slated to expire in July 2026. Catalyst Pharmaceuticals also lost exclusivity for the oral suspension version of Fycompa in December 2025. As a result, revenues from this product are expected to further decline in future periods as additional generic competition enters the market. The reported figure beat the Zacks Consensus Estimate of $13.1 million. Research and development expenses were $2.7 million in the reported quarter, down 32% year over year. Selling, general and administrative expenses totaled $49.3 million, up 5% year over year. As of March 31, 2026, Catalyst Pharmaceuticals had cash, cash equivalents and investments worth $755.9 million compared with $709.2 million as of Dec. 31, 2025. Last week, Catalyst Pharmaceuticals announced settling patent litigation related to Firdapse with Hetero Labs and affiliated companies. The dispute stemmed from Hetero’s abbreviated new drug application seeking approval to market a generic version of the 10 mg tablets before the expiration of relevant patents. Under the settlement, Hetero has received a license to launch a generic version of Firdapse in the United States beginning in January 2035, subject to FDA approval and certain customary exceptions. The agreement also ends all ongoing patent litigation between CPRX, its licensor SERB and Hetero in the U.S. District Court for the District of New Jersey ahead of a scheduled May 2026 trial. It had previously reached similar settlements with Lupin, Teva and Inventia Healthcare regarding generic Firdapse applications. With the Hetero agreement, the company said all pending patent litigation tied to Firdapse has now been resolved. The confidential settlement will be submitted to U.S. antitrust authorities for regulatory review, as required by law. Catalyst Pharmaceuticals is set to be acquired by Angelini Pharma in an all-cash deal valued at about $4.1 billion (€3.5 billion), marking the Italian drugmaker’s entry into the U.S. market. Under the agreement, Catalyst shareholders will receive $31.50 per share in cash, representing a 28% premium to its 30-day volume-weighted average price. The boards of both companies unanimously approved the transaction, which is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals. The acquisition strengthens Angelini Pharma’s focus on brain health and rare neurological diseases by adding Catalyst’s portfolio of approved therapies, including Firdapse for LEMS, Agamree for Duchenne muscular dystrophy and Fycompa for epilepsy. Angelini Pharma plans to combine CPRX’s U.S. commercial infrastructure with its own neuroscience expertise to expand its rare disease platform and broaden its North American presence while maintaining its manufacturing and research footprint in Italy. Catalyst Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Catalyst Pharmaceuticals, Inc. Quote Catalyst Pharmaceuticals currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the biotech sector are Amarin Corporation AMRN, Indivior Pharmaceuticals INDV and Immunocore IMCR, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have also narrowed from $5.50 to $4.64. AMRN shares have risen 7.6% year to date. Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 50.02%. Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV shares have risen 8.2% year to date. Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%. Over the past 60 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 50 cents. On the other hand, its 2026 EPS is currently pegged at 11 cents. IMCR shares have lost 16.9% year to date. Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Intellia Therapeutics NTLA incurred first-quarter 2026 loss of 81 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, the company had incurred a loss of $1.10 per share. Intellia’s total revenues currently comprise only collaboration revenues. The company reported revenues of $15 million for the first quarter of 2026, which missed the Zacks Consensus Estimate of $16 million. Total revenues declined 9.5% year over year. Year to date, shares of NTLA have surged 60.4% against the industry’s 2.7% decline. Image Source: Zacks Investment Research Research and development expenses totaled $80.7 million, down 25.5% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and reduced spending on research materials and contracted services. General and administrative expenses in the first quarter were $34.8 million, up 20.1% year over year, primarily due to continued investments in building the company’s commercial infrastructure and higher legal expenses, partially offset by lower stock-based compensation. As of March 31, 2026, Intellia had cash, cash equivalents and marketable securities worth $517.2 million compared with $605.1 million as of Dec. 31, 2025. Following an underwritten public offering of common stock, the company expects its cash runway to support operations into 2028. Intellia has collaborated with Regeneron Pharmaceuticals REGN to develop its investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM). In March, the FDA lifted the clinical hold on the investigational new drug application (IND) for the phase III MAGNITUDE study evaluating nex-z in patients with ATTR-CM. Earlier this year, the FDA lifted the clinical hold on the IND application for the phase III study, MAGNITUDE-2, evaluating nex-z in patients with ATTRv-PN. Enrollment in this study is expected to be completed in the second half of 2026. With the removal of the clinical hold, Intellia is now focusing on completing patient enrollment in both late-stage studies as promptly as possible. In April, Intellia announced top-line data from the global phase III HAELO study evaluating lonvo-z, an in vivo CRISPR gene editing therapy, for the treatment of hereditary angioedema (HAE). The study met its primary endpoint and all key secondary endpoints. The study demonstrated that a one-time infusion of lonvo-z reduced HAE attacks by 87% compared with placebo over the six-month evaluation period. Patients treated with lonvo-z had a much lower average monthly attack rate (0.26) versus 2.10 in the placebo group. Per data, the company initiated a rolling submission of a biologics license application (BLA) to the FDA seeking approval for lonvo-z for the treatment of HAE. The company expects to complete the BLA submission in the second half of 2026. Intellia plans to commercially launch lonvo-z in the first half of 2027, as the world’s first in vivo CRISPR-based gene editing therapy, if approved. Intellia Therapeutics, Inc. price-consensus-eps-surprise-chart | Intellia Therapeutics, Inc. Quote Intellia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Amarin Corporation AMRN and Indivior Pharmaceuticals INDV, both currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have also narrowed from $5.50 to $4.64. AMRN shares have risen 7.6% year to date. Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 50.02%. Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV shares have risen 8.2% year to date. Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research